The Changes of CTX, DPD, Osteocalcin, and Bone Mineral Density During the Postmenopausal Period
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective To investigate appropriate treatment time and useful bone turnover markers (BTMs) for monitoring bone turnover during the postmenopausal period, we analyzed changes of two bone resorption markers; serum carboxyterminal telopeptide of collagen I (s-CTX), urine deoxypyridinoline (u-DPD), one bone formation marker; serum osteocalcin (s-OC), and bone mineral density (BMD) in Korean postmenopausal women.Methods Seventy-eight menopausal women were divided into three groups according to postmenopausal period: group I (0–5 years), group II (6–10 years), group III (≥10 years). All groups were subdivided into an osteoporosis group (T-score≤-2.5) and a non-osteoporosis group (T-score>-2.5). BTMs such as s-CTX, u-DPD, s-OC, and BMD (g/cm2) were measured by dual-energy X-ray absorptiometry (DXA) in all patients. Analysis of variables among groups based on the postmenopausal period was performed using ANOVA.Results There was significant negative correlation between BMD and postmenopausal period. The levels of all BTMs including s-CTX, u-DPD, and s-OC were highest in group II and the increased levels of all BTMs subsequently declined in group III. The levels of BTMs were higher in the osteoporosis groups than in the non-osteoporosis groups in all subjects. It was statistically significant that the level of s-CTX in group I was higher in the osteoporosis group than in the non-osteoporosis group.Conclusion This study showed that bone resorption and bone formation were the highest 5–10 years after menopause, and s-CTX is more useful than u-DPD among the bone resorption markers. It’s important to measure serially both BMD and BTM within 10 years after menopause for accurate diagnosis and management for postmenopausal osteoporosis.
Abstract
Objective To investigate appropriate treatment time and useful bone turnover markers (BTMs) for monitoring bone turnover during the postmenopausal period, we analyzed changes of two bone resorption markers; serum carboxyterminal telopeptide of collagen I (s-CTX), urine deoxypyridinoline (u-DPD), one bone formation marker; serum osteocalcin (s-OC), and bone mineral density (BMD) in Korean postmenopausal women.Methods Seventy-eight menopausal women were divided into three groups according to postmenopausal period: group I (0–5 years), group II (6–10 years), group III (≥10 years). All groups were subdivided into an osteoporosis group (T-score≤-2.5) and a non-osteoporosis group (T-score>-2.5). BTMs such as s-CTX, u-DPD, s-OC, and BMD (g/cm2) were measured by dual-energy X-ray absorptiometry (DXA) in all patients. Analysis of variables among groups based on the postmenopausal period was performed using ANOVA.Results There was significant negative correlation between BMD and postmenopausal period. The levels of all BTMs including s-CTX, u-DPD, and s-OC were highest in group II and the increased levels of all BTMs subsequently declined in group III. The levels of BTMs were higher in the osteoporosis groups than in the non-osteoporosis groups in all subjects. It was statistically significant that the level of s-CTX in group I was higher in the osteoporosis group than in the non-osteoporosis group.Conclusion This study showed that bone resorption and bone formation were the highest 5–10 years after menopause, and s-CTX is more useful than u-DPD among the bone resorption markers. It’s important to measure serially both BMD and BTM within 10 years after menopause for accurate diagnosis and management for postmenopausal osteoporosis.
참고문헌 (24)
- "Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis", Am J Med, 94, pp.646~650 (1993)[DOI]
- NIH Consensus Development Panel on Osteoporosis Prevention, "Osteoporosis prevention, diagnosis, and therapy", JAMA, 285, pp.785~795 (2001)[DOI]
- 김기찬, "Immobilization Osteoporosis", OSTEOPOROSIS, 9(1), pp.1~17 (2011), 대한골다공증학회
- 김휘동, "Change of Bone Mineral Density and Relationship to Clinical Parameters in Male Stroke Patients", Annals of Rehabilitation Medicine, 40(6), pp.981~988 (2016), 대한재활의학회
- Riggs BL, "Involutional osteoporosis", N Engl J Med, 314, pp.1676~1686 (1986)[DOI]
- 김기찬, "폐경 및 호르몬 대체요법 기간에 따른 골밀도, 골대사 표지자, 지질의 변화", Annals of Rehabilitation Medicine, 25(3), pp.491~497 (2001), 대한재활의학회
- Riggs BL, "The prevention and treatment of osteoporosis", N Engl J Med, 327, pp.620~627 (1992)[DOI]
- Stepan JJ, "Prediction of bone loss in postmenopausal women", Osteoporos Int, 11(Suppl 6), pp.S45~S54 (2000)[DOI]
- Kanis JA, "European guidance for the diagnosis and management of osteoporosis in postmenopausal women", Osteoporos Int, 24, pp.23~57 (2013)[DOI]
- Kanis JA, "A new approach to the development of assessment guidelines for osteoporosis", Osteoporos Int, 13, pp.527~536 (2002)[DOI]
- Vasikaran S, "Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards", Osteoporos Int, 22, pp.391~420 (2011)[DOI]
- 김기찬, "골다공증에서 알렌드로네이트 투여 시 에스트로젠 용량에 따른 치료 효과", Annals of Rehabilitation Medicine, 30(3), pp.247~543 (2006), 대한재활의학회
- Vasikaran SD, "Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis", Crit Rev Clin Lab Sci, 45, pp.221~258 (2008)[DOI]
- Hlaing TT, "Biochemical markers of bone turnover: uses and limitations", Ann Clin Biochem, 51, pp.189~202 (2014)[DOI]
- Garnero P, "Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study", J Bone Miner Res, 15, pp.1526~1536 (2000)[DOI]
- Mun KH, "The biochemical bone marker of the pre and postmenopausal osteoporotic women", J Korean Acad Rehabil Med, 22, pp.93~99 (1998)
- Grampp S, "Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification", J Bone Miner Res, 12, pp.697~711 (1997)[DOI]
- Ivaska KK, "Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk", J Clin Endocrinol Metab, 93, pp.2622~2632 (2008)[DOI]
- Delmas PD, "The use of biochemical markers of bone turnover in osteoporosis", Osteoporos Int, 11(Suppl 6), pp.S2~S17 (2000)[DOI]
- Rosen CJ, "The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation", J Clin Endocrinol Metab, 82, pp.1904~1910 (1997)
- Garnero P, "Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study", J Bone Miner Res, 11, pp.1531~1538 (1996)
- Hochberg MC, "Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents", J Clin Endocrinol Metab, 87, pp.1586~1592 (2002)[DOI]
- Melton LJ, "Relationship of bone turnover to bone density and fractures", J Bone Miner Res, 12, pp.1083~1091 (1997)[DOI]
- Chavassieux P, "Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women", J Clin Endocrinol Metab, 100, pp.4662~4668 (2015)[DOI]